Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2024
Reporting Period: First fiscal quarter ended March 31, 2024
Context: The filing serves to disseminate a press release containing financial and operational information for the Q1 2024 period and recent corporate developments.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text itself does not provide specific values for the following metrics:
- Revenue: Not stated in the filing text.
- Profit/Loss: Not stated in the filing text.
- Cash Flow: Not stated in the filing text.
- Margins: Not stated in the filing text.
- Debt and Liquidity: Not stated in the filing text.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior comparable period. It only indicates that such information is contained within the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release regarding "recent corporate developments" alongside financial results, but does not summarize the content of these developments or any forward-looking guidance within the text of the 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: None identified in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2024) for actual revenue, net loss, and cash position figures.
- Verify the specific details of "recent corporate developments" mentioned in the press release.
- Check for any updated clinical trial milestones or regulatory status updates included in the referenced exhibit.
- Confirm the company's cash runway and burn rate as disclosed in the full press release.